{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:20:38Z","timestamp":1770834038799,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00380-018-1143-3","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T05:15:50Z","timestamp":1519708550000},"page":"965-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial"],"prefix":"10.1007","volume":"33","author":[{"name":"On behalf of the Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Komukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshisato","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hikichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Tago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215\u20132222","journal-title":"Lancet"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"S Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Nj\u00f8lstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors Collaboration (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829\u2013841","journal-title":"N Engl J Med"},{"key":"1143_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12872-016-0422-0","volume":"16","author":"N Li","year":"2016","unstructured":"Li N, Yang YG, Chen MH (2016) Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord 16:238","journal-title":"BMC Cardiovasc Disord"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2013.12.201","volume":"7","author":"KW Park","year":"2014","unstructured":"Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS (2014) Everolimus-eluting Xience v\/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. JACC Cardiovasc Interv 7:471\u2013481","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.amjcard.2010.12.013","volume":"107","author":"T Tada","year":"2011","unstructured":"Tada T, Kimura T, Morimoto T, Ono K, Furukawa Y, Nakagawa Y, Nakashima H, Ito A, Siode N, Namura M, Inoue N, Nishikawa H, Nakao K, Mitsudo K, j-Cypher Registry Investigators (2011) Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 107:1155\u20131162","journal-title":"Am J Cardiol"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1161\/01.CIR.0000129767.45513.71","volume":"109","author":"I Moussa","year":"2004","unstructured":"Moussa I, Leon MB, Baim DS, O\u2019Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW (2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109:2273\u20132278","journal-title":"Circulation"},{"key":"1143_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1253\/circj.CJ-15-1012","volume":"80","author":"T Komatsu","year":"2016","unstructured":"Komatsu T, Komatsu S, Nakamura H, Kuroyanagi T, Fujikake A, Hisauchi I, Sakuma M, Nakahara S, Sakai Y, Taguchi I (2016) Insulin resistance as a predictor of the late catch-up phenomenon after drug-eluting stent implantation. Circ J 80:657\u2013662","journal-title":"Circ J"},{"key":"1143_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MCA.0000000000000170","volume":"26","author":"LP Zhao","year":"2015","unstructured":"Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, Chan SP, Xu HF, Yang XJ (2015) Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis 26:5\u201310","journal-title":"Coron Artery Dis"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jcin.2012.07.008","volume":"5","author":"T Uetani","year":"2012","unstructured":"Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, Harada K, Yoshida T, Kato B, Kato M, Marui N, Nanki M, Hotta N, Ishii H, Matsubara T, Murohara T (2012) Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv 5:1159\u20131167","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/sj.bjp.0707452","volume":"153","author":"CE Quinn","year":"2008","unstructured":"Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE (2008) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636\u2013645","journal-title":"Br J Pharmacol"},{"key":"1143_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2337\/diacare.24.4.710","volume":"24","author":"Y Miyazaki","year":"2001","unstructured":"Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710\u2013719","journal-title":"Diabetes Care"},{"key":"1143_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2005.03.041","volume":"45","author":"A Pfutzner","year":"2005","unstructured":"Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925\u20131931","journal-title":"J Am Coll Cardiol"},{"key":"1143_CR13","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D\u2019Agostino RB Sr, Perez A, Provost JC, Haffner SM (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572\u20132581","journal-title":"JAMA"},{"key":"1143_CR14","doi-asserted-by":"publisher","first-page":"E1076","DOI":"10.1152\/ajpendo.91013.2008","volume":"296","author":"PA Permana","year":"2009","unstructured":"Permana PA, Zhang W, Wabitsch M, Fischer-Posovszky P, Duckworth WC, Reaven PD (2009) Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes\/macrophages. Am J Physiol Endocrinol Metab 296:E1076\u2013E1084","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1143_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/ATVBAHA.112.300346","volume":"33","author":"A Saremi","year":"2013","unstructured":"Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD (2013) Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 33:393\u2013399","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1143_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD, ACT NOW Study (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104\u20131115","journal-title":"N Engl J Med"},{"key":"1143_CR17","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelli\u00e8re R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM, PERISCOPE Investigators (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561\u20131573","journal-title":"JAMA"},{"key":"1143_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijcard.2008.08.031","volume":"138","author":"T Nakayama","year":"2010","unstructured":"Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I (2010) Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 138:157\u2013165","journal-title":"Int J Cardiol"},{"key":"1143_CR19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jcmg.2013.09.004","volume":"6","author":"Y Nitta","year":"2013","unstructured":"Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Ikeda H, Yamagishi S, Imaizumi T (2013) Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET\/CT imaging. JACC Cardiovasc Imaging 6:1172\u20131182","journal-title":"JACC Cardiovasc Imaging"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jcin.2009.04.007","volume":"2","author":"T Takagi","year":"2009","unstructured":"Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J, POPPS Investigators (2009) A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv 2:524\u2013531","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR21","doi-asserted-by":"publisher","first-page":"e0155273","DOI":"10.1371\/journal.pone.0155273","volume":"11","author":"SJ Zhao","year":"2016","unstructured":"Zhao SJ, Zhong ZS, Qi GX, Shi LY, Chen L, Tian W (2016) Effect of pioglitazone in preventing in-stent restenosis after percutaneous coronary intervention in patients with type 2 diabetes: a meta-analysis. PLoS One 11:e0155273","journal-title":"PLoS One"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1161\/CIRCULATIONAHA.105.535484","volume":"112","author":"N Marx","year":"2005","unstructured":"Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M (2005) Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112:2792\u20132798","journal-title":"Circulation"},{"key":"1143_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/heartjnl-2013-304933","volume":"100","author":"S Cassese","year":"2014","unstructured":"Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A (2014) Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 100:153\u2013159","journal-title":"Heart"},{"key":"1143_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacc.2004.12.082","volume":"46","author":"PW Serruys","year":"2005","unstructured":"Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Sch\u00f6nberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F (2005) Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46:575\u2013581","journal-title":"J Am Coll Cardiol"},{"key":"1143_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jcin.2010.10.016","volume":"4","author":"D Patel","year":"2011","unstructured":"Patel D, Walitt B, Lindsay J, Wilensky RL (2011) Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. JACC Cardiovasc Interv 4:353\u2013360","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR26","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1161\/ATVBAHA.110.212670","volume":"30","author":"SJ Hong","year":"2010","unstructured":"Hong SJ, Kim ST, Kim TJ, Kim EO, Ahn CM, Park JH, Kim JS, Lee KM, Lim DS (2010) Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 30:2655\u20132665","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1143_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/01.fjc.0000187176.13403.05","volume":"46","author":"FM Martens","year":"2005","unstructured":"Martens FM, Visseren FL, de Koning EJ, Rabelink TJ (2005) Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46:773\u2013778","journal-title":"J Cardiovasc Pharmacol"},{"key":"1143_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jlb.56.5.559","volume":"56","author":"A Harada","year":"1994","unstructured":"Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56:559\u2013564","journal-title":"J Leukoc Biol"},{"key":"1143_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5551\/jat.E528","volume":"15","author":"M Igarashi","year":"2008","unstructured":"Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M (2008) Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb 15:34\u201340","journal-title":"J Atheroscler Thromb"},{"key":"1143_CR30","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1161\/01.CIR.0000042707.50032.19","volume":"106","author":"Y Okamoto","year":"2002","unstructured":"Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767\u20132770","journal-title":"Circulation"},{"key":"1143_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.lfs.2011.04.001","volume":"88","author":"A Kudoh","year":"2011","unstructured":"Kudoh A, Satoh H, Hirai H, Watanabe T (2011) Pioglitazone upregulates adiponectin receptor 2 in 3T3\u2013L1 adipocytes. Life Sci 88:1055\u20131062","journal-title":"Life Sci"},{"key":"1143_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00125-008-1256-9","volume":"52","author":"DK Coletta","year":"2009","unstructured":"Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA (2009) Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52:723\u2013732","journal-title":"Diabetologia"},{"key":"1143_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2337\/db06-1039","volume":"56","author":"Y Kanatani","year":"2007","unstructured":"Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M (2007) Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56:795\u2013803","journal-title":"Diabetes"},{"key":"1143_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.lfs.2008.09.002","volume":"83","author":"RI Pereira","year":"2008","unstructured":"Pereira RI, Leitner JW, Erickson C, Draznin B (2008) Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3\u2032-kinase. Life Sci 83:638\u2013643","journal-title":"Life Sci"},{"key":"1143_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF03345545","volume":"29","author":"C Otto","year":"2006","unstructured":"Otto C, Otto B, Goke B, Pfeiffer AF, Lehrke M, Vogeser M, Spranger J, Parhofer KG (2006) Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Investig 29:231\u2013236","journal-title":"J Endocrinol Investig"},{"key":"1143_CR36","doi-asserted-by":"publisher","first-page":"34707","DOI":"10.1038\/srep34707","volume":"6","author":"T Kubota","year":"2016","unstructured":"Kubota T, Kubota N, Sato H, Inoue M, Kumagai H, Iwamura T, Takamoto I, Kobayashi T, Moroi M, Terauchi Y, Tobe K, Ueki K, Kadowaki T (2016) Pioglitazone ameliorates smooth muscle cell proliferation in cuff-induced neointimal formation by both adiponectin-dependent and -independent pathways. Sci Rep 6:34707","journal-title":"Sci Rep"},{"key":"1143_CR37","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1253\/circj.CJ-14-0964","volume":"79","author":"SJ Hong","year":"2015","unstructured":"Hong SJ, Choi SC, Cho JY, Joo HJ, Park JH, Yu CW, Lim DS (2015) Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J 79:880\u2013888","journal-title":"Circ J"},{"key":"1143_CR38","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","volume":"54","author":"F Pistrosch","year":"2005","unstructured":"Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P (2005) Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206\u20132211","journal-title":"Diabetes"},{"key":"1143_CR39","doi-asserted-by":"publisher","first-page":"e000364","DOI":"10.1136\/bmjdrc-2016-000364","volume":"5","author":"H Strongman","year":"2017","unstructured":"Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, Majak M, Kool-Houweling L, Linder M, Dolin P, Heintjes EM (2017) Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care 5:e000364","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1143_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.diabres.2015.06.005","volume":"109","author":"H Yokoyama","year":"2015","unstructured":"Yokoyama H, Araki S, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H, Maegawa H, Kashiwagi A (2015) Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Res Clin Pract 109:485\u2013492","journal-title":"Diabetes Res Clin Pract"},{"key":"1143_CR41","doi-asserted-by":"publisher","first-page":"i3477","DOI":"10.1136\/bmj.i3477","volume":"354","author":"J Hippisley-Cox","year":"2016","unstructured":"Hippisley-Cox J, Coupland C (2016) Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 354:i3477","journal-title":"BMJ"},{"key":"1143_CR42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lef\u00e8bvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Kor\u00e1nyi L, Laakso M, Mok\u00e1n M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"1143_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O\u2019Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, Trial Investigators IRIS (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374:1321\u20131331","journal-title":"N Engl J Med"},{"key":"1143_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"M Jong de","year":"2017","unstructured":"de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J (2017) Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 16:134","journal-title":"Cardiovasc Diabetol"},{"key":"1143_CR45","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"HW Liao","year":"2017","unstructured":"Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B (2017) Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 7:e013927","journal-title":"BMJ Open"},{"key":"1143_CR46","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180\u20131188","journal-title":"JAMA"},{"key":"1143_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B (2017) Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 48:388\u2013393","journal-title":"Stroke"},{"key":"1143_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","volume":"11","author":"AV Hernandez","year":"2011","unstructured":"Hernandez AV, Usmani A, Rajamanickam A, Moheet A (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115\u2013128","journal-title":"Am J Cardiovasc Drugs"},{"key":"1143_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/diacare.27.1.256","volume":"27","author":"RW Nesto","year":"2004","unstructured":"Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256\u2013263","journal-title":"Diabetes Care"},{"key":"1143_CR50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm1278","volume":"11","author":"Y Guan","year":"2005","unstructured":"Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861\u2013866","journal-title":"Nat Med"},{"key":"1143_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1139\/cjpp-2015-0135","volume":"94","author":"DM Khodeer","year":"2016","unstructured":"Khodeer DM, Zaitone SA, Farag NE, Moustafa YM (2016) Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE\u2013RAGE axis and inhibition of apoptosis. Can J Physiol Pharmacol 94:463\u2013476","journal-title":"Can J Physiol Pharmacol"},{"key":"1143_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00395-011-0162-3","volume":"106","author":"Y Birnbaum","year":"2011","unstructured":"Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y (2011) Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol 106:431\u2013446","journal-title":"Basic Res Cardiol"},{"key":"1143_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ijcard.2012.01.007","volume":"167","author":"A Sakamoto","year":"2013","unstructured":"Sakamoto A, Hongo M, Furuta K, Saito K, Nagai R, Ishizaka N (2013) Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int J Cardiol 167:409\u2013415","journal-title":"Int J Cardiol"},{"key":"1143_CR54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jjcc.2009.01.011","volume":"53","author":"T Ozawa","year":"2009","unstructured":"Ozawa T, Oda H, Oda M, Hosaka Y, Kashimura T, Ozaki K, Tsuchida K, Takahashi K, Miida T, Aizawa Y (2009) Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: combination therapy with statin. J Cardiol 53:402\u2013409","journal-title":"J Cardiol"},{"key":"1143_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jjcc.2009.03.004","volume":"54","author":"G Terui","year":"2009","unstructured":"Terui G, Goto T, Katsuta M, Aoki I, Ito H (2009) Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol 54:52\u201358","journal-title":"J Cardiol"},{"key":"1143_CR56","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/01.CIR.102.9.1014","volume":"102","author":"K Malmberg","year":"2000","unstructured":"Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014\u20131019","journal-title":"Circulation"},{"key":"1143_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000353679","volume":"36","author":"CJ Lu","year":"2013","unstructured":"Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY (2013) Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis 36:145\u2013151","journal-title":"Cerebrovasc Dis"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-018-1143-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T19:19:05Z","timestamp":1551295145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-018-1143-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s00380-018-1143-3","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HY has received honoraria from Takeda. TU has received honoraria from Daiichi Sankyo, Bayer, Mochida, Boehringer Ingelheim; research funding from Daiichi Sankyo. TI has received honoraria from Mochida and Bayer; and scholarships from Abbott, KAATHU JAPAN, GOODMAN, CLINICO, Shionogi, St. Jude Medical, Daiichi Sankyo, Takeda, Mitsubishi Tanabe, Teijin, Boehringer Ingelheim, Boston Scientific Japan, and UNION TOOL. KNo has received honoraria from Daiichi Sankyo, Merck, Pfizer, Eli Lilly, Amgen, Boehringer Ingelheim, Mitsubishi Tanabe, and Astellas; research funding from Bayer, Teijin, Mitsubishi Tanabe, Astellas, Boehringer Ingelheim, and Asahi Kasei; and scholarships from Astellas, Daiichi Sankyo, Sumitomo Dainippon, Takeda, Mitsubishi Tanabe, and Boehringer Ingelheim. The remaining authors have no financial interests to disclose related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}